探究多药耐药晚期乳腺癌患者采用甲磺酸阿帕替尼单药治疗的效果

Exploring the Effect of Apatinib Mesylate Monotherapy in Patients with Multidrug-resistant Advanced Breast Cancer

目的 探讨采用甲磺酸阿帕替尼对多药耐药晚期乳腺癌患者实施单药治疗后获得临床效果。方法 随机选取2018年1月—2020年12月收治的60例多药耐药晚期乳腺癌患者进行治疗研究;随机分为常规组(采用卡培他滨药物治疗)和研究组(采用甲磺酸阿帕替尼药物治疗),各30例;比较两组患者疾病总控制率及不良反应总发生率。结果 研究组疾病总控制率(93.33%)高于常规组(63.33%),差异有统计学意义(χ^(2)=7.954,P<0.05);研究组不良反应总发生率(20.00%)低于常规组(56.67%),差异有统计学意义(χ^(2)=8.531,P<0.05)。结论 甲磺酸阿帕替尼单药治疗多药耐药晚期乳腺癌,可显著提升疾病控制效果,减少高血压、蛋白尿、高胆红素血症及皮肤反应等系列不良反应发生率,提升患者总体预后水平。

Objective To investigate the clinical effect of apatinib mesylate after monotherapy in patients with multidrug-resistant advanced breast cancer.Methods A total of 60 patients with multidrug-resistant advanced breast cancer who were admitted from January 2018 to December 2020 were randomly selected for treatment research.They were randomly divided into routine group(treated with capecitabine) and study group(treated with apatinib mesylate),30 cases in each group.The overall disease control rate and the overall incidence of adverse reactions were compared between the two groups.Results The overall disease control rate in the study group(93.33%) was higher than that in the routine group(63.33%),and the difference was statistically significant(χ^(2)=7.954,P<0.05).The total incidence of adverse reactions in the study group(20.00%) was lower than that in the routine group(56.67%),and the difference was statistically significant(χ^(2)=8.531,P<0.05).Conclusion After the treatment of apatinib mesylate monotherapy on the multidrug-resistant adranced breast cancer,it can significantly improve the disease control effect,reduce the series of adverse reaction rates such as hypertension,proteinuria,hyperbilirubinemia and skin reactions,and improve the overall prognosis of patients.